Secarna Pharmaceuticals and Vect-Horus Partner to Boost RNA Therapeutics Delivery for CNS Disorders

Secarna Pharmaceuticals and Vect-Horus have launched a strategic research collaboration to develop RNA-targeted therapeutics capable of crossing the blood-brain barrier (BBB) for treating central nervous system (CNS) diseases. The partnership combines Vect-Horus’ VECTrans delivery platform, which uses engineered peptides and antibody vectors to transport therapeutic agents across biological barriers, with Secarna’s AI-driven OligoCreator oligonucleotide discovery platform.

This collaboration aims to overcome one of the biggest challenges in CNS drug development—effective systemic delivery to the brain—potentially transforming treatment options for neurodegenerative and other CNS disorders. VECTrans has already shown promise in preclinical models and clinical-stage programs targeting glioblastoma and pancreatic cancer.

Secarna CEO Konstantin Petropoulos highlighted the strategic importance of the partnership in expanding targeted delivery capabilities, while Vect-Horus CEO Alexandre Tokay emphasized the potential to bring innovative therapies to patients currently facing limited treatment options.

By integrating these complementary technologies, the companies aim to accelerate the development of next-generation RNA therapies that can effectively reach and treat diseases within the CNS.